Pharming has agreed to license AgReasearch its proprietary protein production technology, giving AgResearch responsibility for compound production, including the initial financing of the development program. AgResearch will also support the commercialization of the product through its extensive network in the South Pacific and Asia.
Pharming will have the first right to review new products arising out of AgResearch’s development program. The commercial rights of Pharming will cover recombinant bovine and human proteins produced using its proprietary technology.
Pharming is currently preparing a filing on recombinant human lactoferrin (rhLF) for the FDA to get the product officially recognized as safe. Results from toxicology studies demonstrated that rhLF can be consumed orally at high amounts with no adverse effect.